Merck said it expects its 2022 sales to increase as much as 18% over last year, mostly on sales of its new COVID-19 pill, molnupiravir.


Merck said it expects its 2022 sales to increase as much as 18% over last year, mostly on sales of its new COVID-19 pill, molnupiravir.

Join Investor Signals today and start your journey to better, more disciplined returns.